Virtual Meetings 2022

Meet The Professor: Optimizing the Management of Ovarian Cancer

For up-to-date schedule of upcoming sessions in this series, please click here.

PARTICIPATING FACULTY

Prof Jonathan A Ledermann
Professor of Medical Oncology
UCL Cancer Institute
London, United Kingdom

Stephanie Lheureux, MD, PhD
Drug Development Program ‑ Gynecology
Division of Medical Oncology and Hematology
Gynecology Site Lead
Co-Director of the Beyond Chemotherapy Program
Princess Margaret Cancer Centre
Associate Professor
University of Toronto
Toronto, Ontario, Canada

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts



Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Additional faculty to be announced.

SERIES MODERATOR
Neil Love, MD
Research To Practice

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Mersana Therapeutics Inc.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for ovarian cancer. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Current Treatment Paradigm for Newly Diagnosed and Recurrent Ovarian Cancer

    MODULE 2: Optimal Incorporation of PARP Inhibitors into the Treatment Algorithm

    MODULE 3: Management of Side Effects Associated with PARP Inhibitor Therapy

    MODULE 4: Novel Investigational Agents and Strategies in Ovarian Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of ovarian cancer.

Learning Objectives

  • Consider available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and counsel patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally incorporate these agents into patient care.
  • Appreciate the biologic rationale for and published clinical research data with the use of PARP inhibitors in combination with other systemic therapies, and consider the clinical and research implications of these findings for current and potential OC management.
  • Recognize the rationale for targeting folate receptor alpha and sodium-dependent phosphate transport protein 2b in OC, and consider available and emerging research findings with and the potential role of novel approaches to therapeutically exploit these biomarkers.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for patients with OC, and counsel appropriate individuals about availability and participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof LedermannAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Merck, Merck Sharp & Dohme LLC, Nuvation Bio, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Merck Sharp & Dohme LLC, Neopharm, Tesaro, A GSK Company. Dr LheureuxAdvisory Committee: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline, Merck, Novartis, Novocure Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Regeneron Pharmaceuticals Inc, Repare Therapeutics, Roche Laboratories Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Roche Laboratories Inc. Dr MatulonisAdvisory Committee: 2X Oncology, Agenus Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Clearity Foundation, ImmunoGen Inc, NextCure, Ovarian Cancer Research Alliance, Rivkin Foundation, Trillium Therapeutics Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Novartis; Contracted Research: FUJIFILM Pharmaceuticals USA Inc, ImmunoGen Inc, Merck, Mersana Therapeutics Inc; Data and Safety Monitoring Board/Committee: Advaxis Inc, Alkermes, Symphogen A/S. Dr PensonAdvisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Royalties: BMJ Publishing Group Ltd, Elsevier, Wiley-Blackwell, Wolters Kluwer Health. Dr WestinConsulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, GlaxoSmithKline, Lilly, Merck, Mereo BioPharma, Novartis, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, a member of the Roche Group, GlaxoSmithKline, Mereo BioPharma, Novartis, OncXerna Therapeutics Inc, Zentalis Pharmaceuticals.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Mersana Therapeutics Inc.